Journal Article Review Research Support, Non-U.S. Gov't Epublish 16 citations
PubMed: 39342178 DOI: 10.1186/s12933-024-02434-5
Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review.
Cardiovasc Diabetol 23(1):346
Authors: Haixiang Zheng, Leonardo Antonio Sechi, Eliano Pio Navarese, Gavino Casu, Gianpaolo Vidili
Affiliations
- Department of Biomedical Sciences, University of Sassari, 07100, Sassari, Italy. Department of Cardiology, The Second Affiliated Hospital of Shantou University Medical College, 515041, Shantou, China.
- Department of Biomedical Sciences, University of Sassari, 07100, Sassari, Italy.
- Complex Structure of Microbiology and Virology, AOU Sassari, 07100, Sassari, Italy.
- Clinical and Experimental Cardiology, Clinical and Interventional Cardiology, University of Sassari, Sassari, Italy.
- Department of Medicine, Surgery, and Pharmacy, University of Sassari, Azienda Ospedaliero, 07100, Sassari, Italy.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed nonalcoholic fatty liver disease (NAFLD), poses a significant global health challenge due to its increasing prevalence and strong association with cardiovascular disease (CVD). This comprehensive review summarizes the current knowledge on the MASLD-CVD relationship, compares analysis of how different terminologies for fatty liver disease affect cardiovascular (CV) risk assessment using different diagnostic criteria, explores the pathophysiological mechanisms connecting MASLD to CVD, the influence of MASLD on traditional CV risk factors, the role of noninvasive imaging techniques and biomarkers in the assessment of CV risk in patients with MASLD, and the implications for clinical management and prevention strategies. By incorporating current research and clinical guidelines, this review provides a comprehensive overview of the complex interplay between MASLD and cardiovascular health.
MeSH
Liver Diseases, Non-Alcoholic Fatty Liver Disease, Liver, Fatty Liver, Diabetes Complications
Cited by
- Research progress on AMPK in the pathogenesis and treatment of MASLD. Front Immunol, 2025
- The Perivascular Fat Attenuation Index: Bridging Inflammation and Cardiovascular Disease Risk. J Clin Med, 2025
- Cardiac and liver impairment on multiorgan MRI and risk of major adverse cardiovascular and liver events. Nat Med, 2025
- LncRNA A2ml2 inhibits fatty liver hemorrhage syndrome progression and function as ceRNA to target LPL by sponging miR-143-5p. Poult Sci, 2025
- Noninvasive Assessment of the Severity of Liver Fibrosis in MASLD Patients with Long-Standing Type 2 Diabetes. J Gen Intern Med, 2025
- Metabolic-dysfunction associated steatotic liver disease and atrial fibrillation: A review of pathogenesis. World J Cardiol, 2025
- Advancing Cardiovascular, Kidney, and Metabolic Medicine: A Narrative Review of Insights and Innovations for the Future. Diabetes Ther, 2025
- Association of high-sensitivity C-reactive protein with hepatic fibrosis in patients with metabolic dysfunction-associated steatotic liver disease. Front Immunol, 2025
- Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk. Biomolecules, 2025
- Association between eGDR and accelerated aging: the mediating role of ePWV. Diabetol Metab Syndr, 2025
- Association between cardiovascular health and metabolic dysfunction-associated steatotic liver disease: a nationwide cross-sectional study. J Health Popul Nutr, 2025
- Adherence to the planetary health diet index and metabolic dysfunction-associated steatotic liver disease: a cross-sectional study. Front Nutr, 2025
- Guideline-directed medical strategies for the co-management of heart failure and metabolic dysfunction-associated steatotic liver disease. Commun Med (Lond), 2025
- Goat Whey Protein Hydrolysate Mitigates High-Fructose Corn Syrup-Induced Hepatic Steatosis in a Murine Model. Nutrients, 2025
- Cardiovascular implications of metabolic dysfunction-associated fatty liver disease and type 2 diabetes mellitus: A meta-analysis. World J Hepatol, 2025
- Association between triglyceride-glucose (TyG) related indices and cardiovascular diseases and mortality among individuals with metabolic dysfunction-associated steatotic liver disease: a cohort study of UK Biobank. Cardiovasc Diabetol, 2025
- Use of Metabolic Scores and Lipid Ratios to Predict Metabolic Dysfunction-Associated Steatotic Liver Disease Onset in Patients with Inflammatory Bowel Diseases. J Clin Med, 2025
- Chronic Inflammation and Immune Dysregulation in Metabolic-Dysfunction-Associated Steatotic Liver Disease Progression: From Steatosis to Hepatocellular Carcinoma. Biomedicines, 2025
- Ferroptosis: mechanism and role in diabetes-related cardiovascular diseases. Cardiovasc Diabetol, 2025
- Self-Reported Weight Gain After the Age of 20 and Risk of Steatotic Liver Disease. Nutrients, 2025